Showing results (141-150 of 184) with videos related to
Sort By:
Pageof 19
The Lancet. Gastroenterology & Hepatology|January 28, 2021
SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statementJames L Alexander, Gordon W Moran, Daniel R Gaya, et al.Gut|July 28, 2022
Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemicNicholas A Kennedy, Malik Janjua, Neil Chanchlani, et al.Frontline Gastroenterology|September 3, 2020
Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemicNicholas A Kennedy, Richard Hansen, Lisa Younge, et al.Gastroenterology|October 11, 2019
HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's DiseaseAleksejs Sazonovs, Nicholas A Kennedy, Loukas Moutsianas, et al.Gut|April 27, 2021
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBDNicholas A Kennedy, Simeng Lin, James R Goodhand, et al.Journal of Crohn'S & Colitis|September 2, 2021
Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated PatientsNeil Chanchlani, Simeng Lin, Desmond Chee, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 2, 2021
Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 StudiesRenske W M Pauwels, C Janneke van der Woude, Daan Nieboer, et al.Journal of Gastroenterology and Hepatology|December 31, 2020
Real-world effectiveness and safety of ustekinumab for the treatment of Crohn's disease: the Scottish ustekinumab cohortNikolas Plevris, James Fulforth, Spyros Siakavellas, et al.Alimentary Pharmacology & Therapeutics|October 7, 2014
Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patientsN A Kennedy, R Kalla, B Warner, et al.Ebiomedicine|January 12, 2023
The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patientsJames L Alexander, Benjamin H Mullish, Nathan P Danckert, et al.Pageof 19